7.2 Informed Consent Information and Meaningful Choice

Informed Consent Information and Meaningful Choice

Under the applicable GCP consent process, no investigator may involve a human being as a subject in research unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative (LAR). This protection operationalizes the Belmont principle of Respect for Persons by ensuring individual autonomy, comprehensive disclosure, full comprehension, and complete voluntariness.

The Concept of Informed Consent: Process vs. Document

A common error among novice clinical researchers is treating informed consent as a bureaucratic form to be collected before enrolling a subject. Regulatory authorities and GCP guidelines emphasize that informed consent is an ongoing communicative process:

• Voluntariness: Participation must be entirely voluntary. The prospective participant must be free from any coercion, intimidation, or undue influence from clinicians, family members, or investigators.
• Adequate Time to Consider: Under ICH E6(R3), prior to obtaining consent, the investigator (or designee) must give the subject ample time and opportunity to inquire about details of the trial and to decide whether or not to participate. Assess whether the person actually had adequate information, time and opportunity for questions; a scheduled appointment alone does not establish either adequate or inadequate consent.
• Comprehension and Language: Information must be presented in clear, non-technical language understandable to the subject (adapted to the intended participant population). Technical medical jargon (e.g., "randomized double-blind crossover," "myelosuppression," "pharmacokinetics") must be explained in plain, accessible language.
• Opportunity for Inquiry: All questions asked by the prospective subject or their family must be answered thoroughly to their complete satisfaction.
• Receipt of Documented Copy: Under ICH E6(R3), prior to participation, the subject or LAR must receive a copy of the signed and dated written informed consent form and any other written information provided to the subjects.

Information supporting an informed decision

E6(R3) Annex 1 section 2.8.10 lists information to explain as applicable. Use the current approved materials rather than an R2-era 20-item mnemonic. The discussion covers purpose and experimental aspects; treatment and assignment probability; procedures and responsibilities; foreseeable risks and expected benefits; alternatives; injury treatment/compensation; payments and expenses; voluntariness; and contacts.

It also addresses follow-up after stopping treatment or withdrawing, how data will be handled at discontinuation, confidential direct access to source records, timely new information, reasons participation might end, expected duration and approximate number of participants. Trial results and actual treatment information should be made available when appropriate and when available from the sponsor, respecting whether the participant wants that information.

An information sheet can be complete yet poorly understood. Explain random assignment in ordinary language, distinguish research from individualised care, and avoid promising benefit. Ask the person to describe the main commitments in their own words. A signed form supports documentation; it does not substitute for a voluntary, informed conversation.

Detailed Analysis of Critical Elements

1. Statement of Research: Participants often experience the "therapeutic misconception"—falsely believing that every aspect of the research is tailored specifically to provide optimal individualized medical care. The ICF must explicitly clarify that the trial involves experimental research.

2. Treatment Assignment and Randomization: The participant must understand the concept of randomization, blinding, and the probability of receiving an active investigational drug versus an active comparator or placebo.

3. Foreseeable Risks and Inconveniences: Risks must detail known side effects, their potential severity, reversibility, and likelihood, as well as risks to an embryo, fetus, or nursing infant (including requirements for contraception).

4. Confidential Direct Access to Records: Under ICH E6(R3), the subject must be explicitly informed that monitor(s), auditor(s), regulatory authorities and, where applicable under requirements, the IRB/IEC may have authorised direct access to the subject's original medical records for verification of clinical trial data, without violating confidentiality.

5. Voluntary Withdrawal Without Loss of Benefits: The subject must be informed that refusal to participate or a decision to withdraw at any stage will involve no penalty or loss of benefits to which the subject is otherwise entitled in their routine medical care.

6. Compensation and Treatment for Trial-Related Injury: The document must clearly explain whether free medical treatment, hospitalization, or financial compensation is provided if the subject suffers an injury directly caused by the investigational product or study procedures.

Special Consenting Scenarios and Regulatory Safeguards

Clinical trials frequently encounter prospective participants who face linguistic, cognitive, or physical barriers to standard written consent:

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, WMA Declaration of Helsinki, 2024, ICH E11(R1).